To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04500132

Enrollment

Registered

2020-08-05

Start date

2020-05-28

Completion date

2021-02-15

Last updated

2022-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Prevention of COVID-19 infection to severe pneumonea or ARDS

Interventions

DRUGEC-18

EC-18 QD

DRUGPlacebo EC-18

Placebo EC-18 QD

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed informed consent * Male or female age 19 years or older * Pathologically confirmed diagnosis of COVID-19 Infection to Pneumonia

Exclusion criteria

* Pathologically confirmed diagnosis of bacterial pneumonia or viral pneumonia * Pregnant or nursing at the time of signing informed consent * Known sensitivity to any study medication * Unwilling or unable to complete study diary * Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol

Design outcomes

Primary

Measure	Time frame
Rate of transition to ARDS	14 days after starting IP administration

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026